Division of Cancer Biology (DCB) at the NCI announces the opportunity for current awardees of DCB led programs to apply for supplemental funding to support collaborative research projects under NOT-CA-24-029. The due date is April 12, 2024.
DCB led or co-led programs appropriate for this opportunity include the Acquired Resistance to Therapy Network (ARTNet), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Cellular Cancer Biology Imaging Research (CCBIR) program, the Epstein Barr Virus Associated Lymphoma Consortium (EALC), the Metabolic Dysregulation and Cancer Risk Program (MeDoC), the Metastasis Research Network (MetNet), the Onco-Aging Consortium (OAC), the Oncology Models Forum (OMF), the Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC), the Patient-Derived Models of Cancer Program (PDMC), the Pediatric Immunotherapy Network (PIN), the Physical Sciences-Oncology Network (PS-ON), the Program on the Origins of Gastroesophageal Cancers, and the Translational and Basic Science Research in Early Lesions (TBEL) consortium.
Comments